| abstract |
The invention discloses an estradiol gel, which is composed of an effective dose of estradiol and a gel matrix, wherein the gel matrix contains tyloxapol in an amount of 0.05-2% by weight of the gel. By adding tyloxapol to the gel matrix, the invention improves the transdermal penetration rate and cumulative penetration of estradiol, thereby improving the bioavailability and curative effect of the drug, and at the same time improving the stability of estradiol. properties, preventing it from being degraded or destroyed, thereby improving the shelf life of the drug. |